Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC
J Thorac Oncol 2021 Feb 01;16(2)205-215, X Le, M Nilsson, J Goldman, M Reck, K Nakagawa, T Kato, LP Ares, B Frimodt-Moller, K Wolff, C Visseren-Grul, JV Heymach, EB GaronFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.